ABL类急性淋巴细胞白血病对酪氨酸激酶抑制剂的反应:激酶类型与SH3结构域的作用
约3%的儿童急性淋巴细胞白血病(ALL)存在BCR::ABL1以外的ABL类酪氨酸激酶基因融合。该研究观察了ABL类ALL中不同酪氨酸激酶基因亚组对酪氨酸激酶抑制剂(TKI)敏感性的差异,发现PDGFRB融合样本对达沙替尼和博舒替尼敏感性较低,而各基因亚组对伊马替尼均相对敏感;同一激酶基因亚组内TKI反应的差异与免疫表型、5'融合伴侣、SH2/SH3结构域及IKZF1、PAX5、CDKN2A/B缺失无关。
要点
- ABL类ALL中涉及的酪氨酸激酶基因包括ABL1、PDGFRB、ABL2和CSF1R。
- 任何4种酪氨酸激酶基因融合的ALL样本对伊马替尼均相对敏感。
- PDGFRB融合的ALL样本对达沙替尼和博舒替尼敏感性较低。
核心结论
- ABL类ALL中所涉及的酪氨酸激酶基因是TKI敏感性的主要决定因素,并影响特定TKI的选择。
研究设计与样本
- 观察性研究,评估ABL类ALL样本(占儿童ALL约3%)对TKI的敏感性。
- ABL类酪氨酸激酶基因包括ABL1、PDGFRB、ABL2和CSF1R,每个基因有多达10种已描述的融合伴侣。
主要发现
- 在任何4种酪氨酸激酶基因融合的ALL样本中,均观察到对伊马替尼相对敏感。
- PDGFRB融合的ALL样本对达沙替尼和博舒替尼敏感性较低。
- 同一ABL类酪氨酸激酶基因亚组内TKI反应的差异与ALL免疫表型、5'融合伴侣、Src同源2/3结构域的存在与否、IKZF1、PAX5或CDKN2A/B缺失均无关。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute lymphoblastic leukemia (ALL) with fusions of ABL-class tyrosine kinase genes other than BCR::ABL1 occurs in ∼3% of children with ALL. The tyrosine kinase genes involved in this BCR::ABL1-like (Ph-like) subtype include ABL1, PDGFRB, ABL2, and CSF1R, each of which has up to 10 described partner genes. ABL-class ALL resembles BCR::ABL1-positive ALL with a similar gene expression profile, poor response to chemotherapy, and sensitivity to tyrosine kinase inhibitors (TKIs). There is a lack of comprehensive data regarding TKI sensitivity in the heterogeneous group of ABL-class ALL. We observed variability in TKI sensitivity within and among each ABL-class tyrosine kinase gene subgroup. We showed that ALL samples with fusions for any of the 4 tyrosine kinase genes were relatively sensitive to imatinib. In contrast, the PDGFRB-fused ALL samples were less sensitive to dasatinib and bosutinib. Variation in ex vivo TKI response within the subset of samples with the same ABL-class tyrosine kinase gene was not associated with the ALL immunophenotype, 5' fusion partner, presence or absence of Src-homology-2/3 domains, or deletions of IKZF1, PAX5, or CDKN2A/B. In conclusion, the tyrosine kinase gene involved in ABL-class ALL is the main determinant of TKI sensitivity and relevant for specific TKI selection.
引用
- van Outersterp I, Tasian SK, Reichert CEJ, et al. Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain. Blood. 2024. PMID: 38394665. doi:10.1182/blood.2023023120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。